Literature DB >> 12812988

Nucleocytoplasmic transport signals affect the age at onset of abnormalities in knock-in mice expressing polyglutamine within an ectopic protein context.

Walker S Jackson1, Sara J Tallaksen-Greene, Roger L Albin, Peter J Detloff.   

Abstract

In order to better understand the role of nuclear localization of polyglutamine in the human CAG repeat disorders, gene targeting was used to add either nuclear localization (NLS) or nuclear export (NES) signals to versions of the mouse Hprt protein containing expanded polyglutamine (HprtQ150). The NLS increased levels of nuclear HprtQ150 protein in the mouse brain and hastened both the presentation of neuronal intranuclear inclusions (NIIs) and the onset of behavioral abnormalities. The NES reduced levels of nuclear HprtQ150 protein in mouse brain and delayed both the presentation of NIIs and the onset of behavioral abnormalities. Together these results indicate the nucleus is the primary site of toxicity in HprtQ150 mice. Furthermore, the signals did not alter the relative regional distribution of NIIs, suggesting that factors other than nuclear access dictate the regional specificity of NII formation in this mouse model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12812988     DOI: 10.1093/hmg/ddg163

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  14 in total

1.  Assessment of locomotion in chlorine exposed mice by computer vision and neural networks.

Authors:  Aristotelis S Filippidis; Sotirios G Zarogiannis; Alan Randich; Timothy J Ness; Sadis Matalon
Journal:  J Appl Physiol (1985)       Date:  2011-12-29

2.  Automated home-cage behavioural phenotyping of mice.

Authors:  Hueihan Jhuang; Estibaliz Garrote; Jim Mutch; Xinlin Yu; Vinita Khilnani; Tomaso Poggio; Andrew D Steele; Thomas Serre
Journal:  Nat Commun       Date:  2010-09-07       Impact factor: 14.919

Review 3.  Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.

Authors:  Masahisa Katsuno; Hiroaki Adachi; Fumiaki Tanaka; Gen Sobue
Journal:  J Mol Med (Berl)       Date:  2004-02-27       Impact factor: 4.599

Review 4.  Transcriptional signatures in Huntington's disease.

Authors:  Jang-Ho J Cha
Journal:  Prog Neurobiol       Date:  2007-04-01       Impact factor: 11.685

5.  Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner.

Authors:  Caroline L Benn; Tingting Sun; Ghazaleh Sadri-Vakili; Karen N McFarland; Derek P DiRocco; George J Yohrling; Timothy W Clark; Bérengère Bouzou; Jang-Ho J Cha
Journal:  J Neurosci       Date:  2008-10-15       Impact factor: 6.167

Review 6.  Polyglutamine Repeats in Neurodegenerative Diseases.

Authors:  Andrew P Lieberman; Vikram G Shakkottai; Roger L Albin
Journal:  Annu Rev Pathol       Date:  2018-08-08       Impact factor: 23.472

7.  CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse.

Authors:  I Dragatsis; D Goldowitz; N Del Mar; Y P Deng; C A Meade; Li Liu; Z Sun; P Dietrich; J Yue; A Reiner
Journal:  Neurobiol Dis       Date:  2008-11-06       Impact factor: 5.996

8.  Translation of the prion protein mRNA is robust in astrocytes but does not amplify during reactive astrocytosis in the mouse brain.

Authors:  Walker S Jackson; Clemens Krost; Andrew W Borkowski; Lech Kaczmarczyk
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

9.  Nucleocytoplasmic shuttling activity of ataxin-3.

Authors:  Sandra Macedo-Ribeiro; Luísa Cortes; Patrícia Maciel; Ana Luísa Carvalho
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

10.  Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin.

Authors:  Chuan-En Wang; Hui Zhou; John R McGuire; Vincenzo Cerullo; Brendan Lee; Shi-Hua Li; Xiao-Jiang Li
Journal:  J Cell Biol       Date:  2008-05-26       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.